https://flare.lucidgraphics.co.uk/presentations/ 2025-11-07T12:27:42+00:00 https://flare.lucidgraphics.co.uk/presentations/a-phase-1-first-in-human-dose-escalation-and-expansion-study-of-fx-909-in-patients-with-advanced-solid-malignancies-including-advanced-urothelial-carcinoma/ 2024-03-15T05:45:28+00:00 https://flare.lucidgraphics.co.uk/presentations/pparg-amplification-is-associated-with-lack-of-response-to-anti-pd1-in-muscle-invasive-urothelial-cancer/ 2024-03-15T05:47:28+00:00 https://flare.lucidgraphics.co.uk/presentations/ai-analysis-of-histological-images-accurately-identifies-luminal-subtype-urothelial-carcinomas-characterized-by-high-pparg-expression/ 2024-03-15T05:47:36+00:00 https://flare.lucidgraphics.co.uk/presentations/development-of-a-surrogate-tissue-pharmacodynamic-pd-assay-for-potential-clinical-use-with-fx-909-a-novel-inhibitor-of-the-urothelial-luminal-lineage-transcription-factor-peroxisome-proliferator-ac/ 2024-03-15T05:48:04+00:00 https://flare.lucidgraphics.co.uk/presentations/novel-inhibitors-of-the-luminal-lineage-transcription-factor-peroxisome-proliferator-activated-receptor-gamma-pparg-durably-eradicate-tumors-in-urothelial-cancer-uc-animal-models/ 2024-03-15T05:48:20+00:00 https://flare.lucidgraphics.co.uk/presentations/peroxisome-proliferator-activated-receptor-gamma-pparg-status-defines-the-luminal-lineage-in-molecular-profiles-of-advanced-urothelial-cancers-uc/ 2024-03-15T05:48:28+00:00 https://flare.lucidgraphics.co.uk/presentations/nat-biotechnol-reimagining-high-throughput-profiling-of-reactive-cysteines-for-cell-based-screening-of-large-electrophile-libraries/ 2024-03-15T05:48:40+00:00 https://flare.lucidgraphics.co.uk/presentations/nat-chem-biol-bidirectional-modulation-of-hif-2-activity-through-chemical-ligands/ 2024-03-15T05:48:59+00:00 https://flare.lucidgraphics.co.uk/presentations/cell-the-human-transcription-factors/ 2024-03-15T05:49:07+00:00 https://flare.lucidgraphics.co.uk/presentations/wp-content-uploads-2024-04-flaretx-aacr-poster-69x45-mar24-v7a-wcropsbleeds-ultra-hires-pdf/ 2024-05-17T15:57:52+00:00 https://flare.lucidgraphics.co.uk/presentations/genomic-peroxisome-proliferator-activated-receptor-gamma-pparg-study-a-sponsored-testing-program-to-identify-patients-harboring-genetic-alterations-in-advanced-uc-in-support-of-the-fx-909-phase-1-s/ 2024-05-17T17:22:51+00:00 https://flare.lucidgraphics.co.uk/presentations/pparg-protein-expression-in-advanced-urothelial-carcinoma-may-provide-a-precision-approach-to-potentially-select-for-response-to-fx-909-a-first-in-class-pparg-targeting-agent/ 2025-06-11T15:24:08+00:00 https://flare.lucidgraphics.co.uk/presentations/webinar-presentation-of-fx-909-phase-1-part-a-data-in-advanced-solid-malignancies-including-advanced-urothelial-carcinoma/ 2025-10-24T16:00:42+00:00 https://flare.lucidgraphics.co.uk/presentations/safety-and-clinical-activity-of-fx-909-a-first-in-class-oral-small-molecule-inhibitor-of-peroxisome-proliferator-activated-receptor-gamma-pparg-the-master-regulator-of-luminal-lineage-in-patients/ 2025-10-24T16:00:56+00:00 https://flare.lucidgraphics.co.uk/presentations/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-oral-presentation-of-fx-909-phase-1a-clinical-data/ 2025-10-24T16:10:07+00:00 https://flare.lucidgraphics.co.uk/presentations/phase-1-clinical-data-show-fx-909-a-first-in-class-oral-pparg-inhibitor-drives-immune-modulation-and-pro-inflammatory-cytokine-induction-in-io-experienced-patients-with-advanced-urothelial-carcinoma/ 2025-11-08T15:00:44+00:00